PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of canmedajCMAJ Information for AuthorsCMAJ Home Page
 
Can Med Assoc J. 1980 July 5; 123(1): 23–26.
PMCID: PMC1704538

Clonidine (Dixarit) for menopausal flushing.

Abstract

Clonidine, 0.05 mg twice daily, was evaluated in a multicentre, randomized, placebo-controlled, double-blind crossover study in 66 patients who had had menopausal flushing for less than 1 year. Although the placebo effect was substantial, clonidine reduced the frequency of attacks significantly more than did placebo. In three of the four trials the patients' comparisons of symptoms before and after crossover indicated significantly greater improvement when the crossover was from placebo to clonidine rather than the reverse. The frequency, severity and duration of attacks were reduced by clonidine in 78%, 89% and 88% of the patients respectively, and by placebo in 50%, 53% and 50%. Side effects were minimal and their pattern was the same for clonidine as for placebo. Clonidine's action as a peripheral vascular stabilizer makes it potentially useful for the treatment of menopausal flushing. It would be prudent to include clonidine at the beginning of treatment so that its efficacy could be assessed in each individual. Its use would enhance the effects of the usual management of the menopausal syndrome, which consists of explanation, reassurance and, sometimes, the use of tranquillizers. Clonidine is a symptomatic medication that makes flushing more tolerable and should reduce the number of patients who would otherwise be exposed to the risks of estrogens.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (790K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Mulley G, Mitchell JR. Menopausal flushing: does oestrogen therapy make sense? Lancet. 1976 Jun 26;1(7974):1397–1399. [PubMed]
  • Zaimis E, Hanington E. A possible pharmacological approach to migraine. Lancet. 1969 Aug 9;2(7615):298–300. [PubMed]
  • Gaskell P, Melnyk J. The effect of clonidine on vascular reactivity to angiotensin, noradrenaline, and vasopressin in conscious rats. Can J Physiol Pharmacol. 1978 Feb;56(1):23–29. [PubMed]
  • Shafar J, Tallett ER, Knowlson PA. Evaluation of clonidine in prophylaxis of migraine. Double-blind trial and follow-up. Lancet. 1972 Feb 19;1(7747):403–407. [PubMed]
  • Clayden JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J. 1974 Mar 9;1(5905):409–412. [PMC free article] [PubMed]
  • Ylikorkala O. Clonidine in the treatment of menopausal symptoms. Ann Chir Gynaecol Fenn. 1975;64(4):242–245. [PubMed]
  • Otto G, Uhlig K. Hormonale Kontrazeptiva und Leberschäden. Z Arztl Fortbild (Jena) 1974 Nov 1;68(21):1181–1183. [PubMed]
  • Linquette M, Gasnault JP, Dupont-Lecompte J, Racadot A. L'hyperoestrogénie des cirrhoses. Etude chromatographique et test de charge zu benzoate d'oestradiol. Sem Hop. 1967 Oct 26;43(44):2714–2728. [PubMed]
  • Coope J, Thomson JM, Poller L. Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J. 1975 Oct 18;4(5989):139–143. [PMC free article] [PubMed]
  • Oski FA, Lubin B, Buchert ED. Reduced red cell filterability with oral contraceptive agents. Ann Intern Med. 1972 Sep;77(3):417–419. [PubMed]
  • Austad WI, Hamilton-Gibbs JS. Porphyria cutanea tarda and the pill: case report. N Z Med J. 1975 Jan 8;81(531):8–10. [PubMed]
  • Irey NS, Manion WC, Taylor HB. Vascular lesions in women taking oral contraceptives. Arch Pathol. 1970 Jan;89(1):1–8. [PubMed]
  • Hoover R, Gray LA, Sr, Cole P, MacMahon B. Menopausal estrogens and breast cancer. N Engl J Med. 1976 Aug 19;295(8):401–405. [PubMed]
  • Aleem FA, Moukhtar MA, Hung HC, Romney SL. Plasma estrogen in patients with endometrial hyperplasia and carcinoma. Cancer. 1976 Nov;38(5):2101–2104. [PubMed]
  • Saruta T, Saade GA, Kaplan NM. A possible mechanism for hypertension induced by oral contraceptives. Diminished feedback suppression of renin release. Arch Intern Med. 1970 Oct;126(4):621–626. [PubMed]
  • Lageder H. Carbohydrate metabolism and hormonal replacement therapy: problems and clinical results. Acta Obstet Gynecol Scand Suppl. 1977;65:57–63. [PubMed]
  • Strickler RC, Borth R, Woodlever CA. The climacteric syndrome: an estrogen replacement dilemma. Can Med Assoc J. 1977 Mar 19;116(6):586–587. [PMC free article] [PubMed]
  • Coope J, Thomson JM, Poller L. Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J. 1975 Oct 18;4(5989):139–143. [PMC free article] [PubMed]
  • Evans J, Hailes J. Low-dosage clonidine (Dixarit) in menopausal flushing. Med J Aust. 1979 Jul 14;2(1):45–46. [PubMed]
  • Bolli P, Simpson FO. Clonidine in menopausal flushing: a double-blind trial. N Z Med J. 1975 Sep 24;82(548):196–197. [PubMed]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association